Relmada Therapeutics, Inc.
DE ˙ DB ˙ US75955J4022
€5.30 ↓ -0.05 (-0.93%)
2026-06-04
주가
SecurityDE:4E2 / Relmada Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership198,463 shares
Latest Disclosed Value $ 1,381,303
Morgan Stanley reports 218.27% increase in ownership of 4E2 / Relmada Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 198,463 shares of Relmada Therapeutics, Inc. (DE:4E2) valued at $1,091,546 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 62,357 shares of Relmada Therapeutics, Inc.. This represents a change in shares of 218.27% during the quarter. The current value of the position is $1,051,854 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RELMADA THERAPEUTICS COM 75955J402 198,463 136,106 218.27 1,381 358.80 0.0001
2026-05-27 2025-12-31 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 62,357 61,318 5,901.64 301 14,950.00 0.0000
2026-02-13 2025-12-31 13F RELMADA THERAPEUTICS COM 75955J402 62,357 61,318 301 0.0000
2026-05-27 2025-09-30 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 1,039 187 21.95 2 0.0000
2025-11-14 2025-09-30 13F RELMADA THERAPEUTICS COM 75955J402 1,039 187 2 0.0000
2025-08-15 2025-06-30 13F RELMADA THERAPEUTICS COM 75955J402 852 -1,316 -60.70 1 0.0000
2025-05-15 2025-03-31 13F RELMADA THERAPEUTICS COM 75955J402 2,168 -15,029 -87.39 1 -100.00 0.0000
2025-05-15 2024-12-31 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 17,197 -20,680 -54.60 9 -93.44 0.0000
2025-02-14 2024-12-31 13F RELMADA THERAPEUTICS COM 75955J402 17,197 -20,680 9 0.0000
2025-05-14 2024-09-30 13F/A-2 RELMADA THERAPEUTICS COM 75955J402 37,877 -8,299 -17.97 123 -11.59 0.0000
2025-02-14 2024-09-30 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 37,877 -8,299 123 0.0000
2024-11-14 2024-09-30 13F RELMADA THERAPEUTICS COM 75955J402 37,877 -8,299 123 0.0000
2025-05-14 2024-06-30 13F/A-2 RELMADA THERAPEUTICS COM 75955J402 46,176 -74,338 -61.68 139 -75.36 0.0000
2024-10-17 2024-06-30 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 46,176 -74,338 139 0.0000
2024-08-14 2024-06-30 13F RELMADA THERAPEUTICS COM 75955J402 46,176 -74,338 139 0.0000
2024-10-17 2024-03-31 13F/A-2 RELMADA THERAPEUTICS COM 75955J402 120,514 30,404 33.74 560 50.13 0.0000
2024-08-16 2024-03-31 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 120,514 30,404 560 0.0000
2024-05-15 2024-03-31 13F RELMADA THERAPEUTICS COM 75955J402 120,514 30,404 560 0.0000
2024-08-16 2023-12-31 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 90,110 -33,227 -26.94 373 0.81 0.0000
2024-02-13 2023-12-31 13F RELMADA THERAPEUTICS COM 75955J402 90,110 -33,227 373 0.0000
2023-11-15 2023-09-30 13F RELMADA THERAPEUTICS COM 75955J402 123,337 -79,400 -39.16 370 -25.70 0.0000
2023-08-14 2023-06-30 13F RELMADA THERAPEUTICS COM 75955J402 202,737 -145,137 -41.72 499 -36.64 0.0000
2023-05-15 2023-03-31 13F RELMADA THERAPEUTICS COM 75955J402 347,874 -140,865 -28.82 786 -53.90 0.0001
2023-02-14 2022-12-31 13F RELMADA THERAPEUTICS COM 75955J402 488,739 196,129 67.03 1,706 -84.26 0.0002
2022-11-14 2022-09-30 13F RELMADA THERAPEUTICS COM 75955J402 292,610 -22,627 -7.18 10,831 80.94 0.0015
2022-10-27 2022-06-30 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 315,237 49,172 18.48 5,986 -16.64 0.0008
2022-08-15 2022-06-30 13F RELMADA THERAPEUTICS COM 75955J402 315,237 49,172 5,986 0.0002
2022-10-27 2022-03-31 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 266,065 -307,256 -53.59 7,181 -44.41 0.0010
2022-05-13 2022-03-31 13F RELMADA THERAPEUTICS COM 75955J402 266,065 -307,256 7,181 0.0010
2022-02-14 2021-12-31 13F RELMADA THERAPEUTICS COM 75955J402 573,321 123,980 27.59 12,917 9.68 0.0016
2021-11-15 2021-09-30 13F RELMADA THERAPEUTICS COM 75955J402 449,341 422,982 1,604.70 11,777 1,295.38 0.0016
2021-08-23 2021-06-30 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 26,359 25,205 2,184.14 844 1,958.54 0.0001
2021-08-16 2021-06-30 13F RELMADA THERAPEUTICS COM 75955J402 26,359 25,205 844 0.0000
2021-05-17 2021-03-31 13F RELMADA THERAPEUTICS COM 75955J402 1,154 -10,462 -90.07 41 -89.01 0.0000
2021-02-16 2020-12-31 13F RELMADA THERAPEUTICS COM 75955J402 11,616 -1,828 -13.60 373 -26.28 0.0001
2020-11-13 2020-09-30 13F RELMADA THERAPEUTICS COM 75955J402 13,444 -32,443 -70.70 506 -75.35 0.0001
2020-08-14 2020-06-30 13F RELMADA THERAPEUTICS COM 75955J402 45,887 45,111 5,813.27 2,053 7,796.15 0.0005
2020-05-26 2020-03-31 13F/A-1 RELMADA THERAPEUTICS COM 75955J402 776 -5,972 -88.50 26 -90.11 0.0000
2020-05-15 2020-03-31 13F RELMADA THERAPEUTICS COM 75955J402 776 -5,972 26 1.9973
2020-02-14 2019-12-31 13F RELMADA THERAPEUTICS COM 75955J402 6,748 6,748 263 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.